- A high growth CDMO with integrated capabilities across the drug development lifecycle, including high-demand areas of sterile fill-finish drug product manufacturing, biologic and small molecule lab services, cGMP biostorage and pharma services
- Recent acquisitions and significant investment in new capacity and state of the art lab space will support Alcami’s continued high growth potential
- GHO Capital and The Vistria Group to support the Alcami team in the build out of capabilities and international expansion
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, and The Vistria Group, a middle-market private investment firm focused on delivering financial returns and societal impact, today announced that they have entered into a definitive agreement to acquire a controlling interest in Alcami Corporation (“Alcami”), a pharmaceutical contract development and manufacturing organisation (CDMO), from funds affiliated with Madison Dearborn Partners (“MDP”) and Ampersand Capital Partners (“Ampersand”).
Headquartered in North Carolina, Alcami has built a strong offering, market position, and reputation in high-growth specialties including drug product manufacturing focusing on sterile fill-finish of both biologics and small molecules; formulation development; lab services; and cGMP biostorage of high-value temperature-sensitive biologics, pharmaceuticals, and materials.
Alcami enacted a major strategic transformation, enhancing the growth profile of the business. Building on a strong service offering, Alcami acquired a world-class sterile fill-finish operation in TriPharm Services, and in December 2021 acquired Masy BioServices, a premier cGMP biostorage and pharma services business. In addition, Alcami has invested over $140 million in capital expenditure to add five state-of-the-art sterile fill-finish manufacturing lines and additional laboratory space to support both biologic and small molecule programs.